Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma

Cancer Cell. 2014 May 12;25(5):560-2. doi: 10.1016/j.ccr.2014.04.019.

Abstract

Focal amplifications in 6p21 containing the VEGFA locus occur in 7%-10% of hepatocellular carcinoma (HCC). A recent paper describes how VEGF-A stimulates paracrine secretion of hepatocyte growth factor by stromal cells, which induces tumor progression. HCC patients with VEGFA amplification are distinctly sensitive to sorafenib.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Hepatocellular / drug therapy*
  • Cell Proliferation
  • Disease Progression
  • Drug Resistance, Neoplasm*
  • Gene Amplification
  • Hepatocyte Growth Factor / metabolism
  • Humans
  • Liver Neoplasms / drug therapy
  • Macrophages
  • Mice
  • Niacinamide / analogs & derivatives*
  • Niacinamide / therapeutic use
  • Phenylurea Compounds / therapeutic use*
  • Sorafenib
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / genetics
  • Vascular Endothelial Growth Factor A / metabolism*

Substances

  • Antineoplastic Agents
  • Phenylurea Compounds
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Niacinamide
  • Hepatocyte Growth Factor
  • Sorafenib